In the afternoon, we will see if Wuxi PharmaTech has a chance to reply, which will have an important impact on the continued adjustment of the market or index. The change of daily limit data also deserves close attention. However, in general, the decline of high-level stocks, especially the influence of core stocks such as CAMBRIAN, can not be ignored. The market is full of changes and opportunities, and we need to be vigilant and keen at all times in order to capture our own opportunities in it.At midday, the key analysis targets are for reference only, and accordingly, the operation is at its own risk.
Be cautious about high-end stocks stepping backAt midday, the key analysis targets are for reference only, and accordingly, the operation is at its own risk.Be cautious about high-end stocks stepping back
Last Friday's market performance was full of changes and opportunities. The daily limit is less than expected, and the high-low switch is obvious, which shows the caution and keenness of market funds. WuXi PharmaTech benefited from the MG Medicine Act, but it failed to continue to strengthen, and the pressure and market reaction were clear at a glance.In the afternoon, we will see if Wuxi PharmaTech has a chance to reply, which will have an important impact on the continued adjustment of the market or index. The change of daily limit data also deserves close attention. However, in general, the decline of high-level stocks, especially the influence of core stocks such as CAMBRIAN, can not be ignored. The market is full of changes and opportunities, and we need to be vigilant and keen at all times in order to capture our own opportunities in it.Be cautious about high-end stocks stepping back
Strategy guide 12-13
Strategy guide
12-13